Compare Smith & Nephew plc (SNN) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Materials Select Sector SPDR Fund — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| SNN | XLB | |
|---|---|---|
Market Cap | $11.10B | $7.73B |
Volume | 1,051,703 | 13,681,146 |
Sector | Health | — |
52-Week High | $37.17 | $53.67 |
52-Week Low | $26.42 | $42.23 |
Typical Hold Time | 121 Days | 70 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
XLB trades at $49.43, up 0.92% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent news highlights materials as a potential 'anti-AI' play but questions near-term valuation after recent rebounds.
Outlook remains cautious given technical weakness and sector cyclicality. Investment opportunity exists for long-term infrastructure exposure, but risks include overconcentration in chemicals and potential earnings volatility. Current levels near support at $49 require monitoring for breakdown confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
